These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23813283)

  • 41. On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials.
    Wick WD; Gilbert PB; Self SG
    PLoS Comput Biol; 2006 Jun; 2(6):e64. PubMed ID: 16789816
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estimating and Testing Vaccine Sieve Effects Using Machine Learning.
    Benkeser D; Gilbert PB; Carone M
    J Am Stat Assoc; 2019; 114(527):1038-1049. PubMed ID: 31649413
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The cost-effectiveness of a modestly effective HIV vaccine in the United States.
    Long EF; Owens DK
    Vaccine; 2011 Aug; 29(36):6113-24. PubMed ID: 21510996
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advances in HIV-1 Vaccine Development.
    Gao Y; McKay PF; Mann JFS
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29614779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sensitivity analyses comparing outcomes only existing in a subset selected post-randomization, conditional on covariates, with application to HIV vaccine trials.
    Shepherd BE; Gilbert PB; Jemiai Y; Rotnitzky A
    Biometrics; 2006 Jun; 62(2):332-42. PubMed ID: 16918897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are Clade Specific HIV Vaccines a Necessity? An Analysis Based on Mathematical Models.
    Dimitrov D; Kublin JG; Ramsey S; Corey L
    EBioMedicine; 2015 Dec; 2(12):2062-9. PubMed ID: 26844286
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy.
    Datta S; Halloran ME; Longini IM
    Stat Med; 1998 Jan; 17(2):185-200. PubMed ID: 9483728
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predicting Overall Vaccine Efficacy in a New Setting by Re-Calibrating Baseline Covariate and Intermediate Response Endpoint Effect Modifiers of Type-Specific Vaccine Efficacy.
    Gilbert PB; Huang Y
    Epidemiol Methods; 2016 Dec; 5(1):93-112. PubMed ID: 28154793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lessons from the RV144 Thai phase III HIV-1 vaccine trial and the search for correlates of protection.
    Kim JH; Excler JL; Michael NL
    Annu Rev Med; 2015; 66():423-37. PubMed ID: 25341006
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
    Rerks-Ngarm S; Pitisuttithum P; Excler JL; Nitayaphan S; Kaewkungwal J; Premsri N; Kunasol P; Karasavvas N; Schuetz A; Ngauy V; Sinangil F; Dawson P; deCamp AC; Phogat S; Garunathan S; Tartaglia J; DiazGranados C; Ratto-Kim S; Pegu P; Eller M; Karnasuta C; Montefiori DC; Sawant S; Vandergrift N; Wills S; Tomaras GD; Robb ML; Michael NL; Kim JH; Vasan S; O'Connell RJ;
    J Infect Dis; 2017 Apr; 215(8):1255-1263. PubMed ID: 28329190
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Parametric mixture models to evaluate and summarize hazard ratios in the presence of competing risks with time-dependent hazards and delayed entry.
    Lau B; Cole SR; Gange SJ
    Stat Med; 2011 Mar; 30(6):654-65. PubMed ID: 21337360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lessons learned from HIV vaccine clinical efficacy trials.
    Day TA; Kublin JG
    Curr HIV Res; 2013 Sep; 11(6):441-9. PubMed ID: 24033299
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A unified evaluation of differential vaccine efficacy.
    Gabriel EE; Sachs MC; Follmann DA; Andersson TM
    Biometrics; 2020 Dec; 76(4):1053-1063. PubMed ID: 31868914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Case-sibling gene-association studies for diseases with variable age at onset.
    Kraft P; Thomas DC
    Stat Med; 2004 Dec; 23(23):3697-712. PubMed ID: 15534888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide.
    Rolland M; Gilbert P
    AIDS Res Hum Retroviruses; 2012 Apr; 28(4):400-4. PubMed ID: 21902593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved estimation of the cumulative incidence of rare outcomes.
    Benkeser D; Carone M; Gilbert PB
    Stat Med; 2018 Jan; 37(2):280-293. PubMed ID: 28670687
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
    Buchbinder SP; Mehrotra DV; Duerr A; Fitzgerald DW; Mogg R; Li D; Gilbert PB; Lama JR; Marmor M; Del Rio C; McElrath MJ; Casimiro DR; Gottesdiener KM; Chodakewitz JA; Corey L; Robertson MN;
    Lancet; 2008 Nov; 372(9653):1881-1893. PubMed ID: 19012954
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.
    Gottardo R; Bailer RT; Korber BT; Gnanakaran S; Phillips J; Shen X; Tomaras GD; Turk E; Imholte G; Eckler L; Wenschuh H; Zerweck J; Greene K; Gao H; Berman PW; Francis D; Sinangil F; Lee C; Nitayaphan S; Rerks-Ngarm S; Kaewkungwal J; Pitisuttithum P; Tartaglia J; Robb ML; Michael NL; Kim JH; Zolla-Pazner S; Haynes BF; Mascola JR; Self S; Gilbert P; Montefiori DC
    PLoS One; 2013; 8(9):e75665. PubMed ID: 24086607
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting and vaccine durability are key for population-level impact and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa.
    Selinger C; Bershteyn A; Dimitrov DT; Adamson BJS; Revill P; Hallett TB; Phillips AN; Bekker LG; Rees H; Gray G
    Vaccine; 2019 Apr; 37(16):2258-2267. PubMed ID: 30890385
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    Pissani F; Schulte B; Eller MA; Schultz BT; Ratto-Kim S; Marovich M; Thongcharoen P; Sriplienchan S; Rerks-Ngarm S; Pitisuttithum P; Esser S; Alter G; Robb ML; Kim JH; Michael NL; Streeck H
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30209165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.